{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:44:28Z","timestamp":1780487068627,"version":"3.54.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Although infrequently encountered, the diagnosis of ovarian high-grade endometrioid carcinoma remains a diagnostic challenge with potential consequences for targeted therapies and genetic counselling. We studied the clinical, morphologic, and immunohistochemical features of ovarian high-grade endometrioid carcinomas and their diagnostic reproducibility compared with tuboovarian high-grade serous carcinomas. Thirty cases confirmed as International Federation of Gynecology and Obstetrics grade 3 endometrioid carcinomas were identified from 182 ovarian endometrioid carcinomas diagnosed in Alberta, Canada, between 1978 and 2010, from the population-based Alberta Ovarian Tumor Types cohort. Cases of lower grade endometrioid and high-grade serous carcinoma served for comparison. Ten immunohistochemical markers were assessed on tissue microarrays. Clinical data were abstracted and survival analyses performed using Cox regression. Interobserver reproducibility for histologic type was assessed using 1 representative hematoxylin and eosin\u2013stained slide from 25 randomly selected grade 3 endometrioid carcinomas and 25 high-grade serous carcinomas. Histotype was independently assigned by 5 pathologists initially blinded to immunohistochemical WT1\/p53 status, with subsequent reassessment unblinded to WT1\/p53 status. Patients diagnosed with grade 3 endometrioid carcinoma had a significantly longer survival compared with high-grade serous carcinoma in univariate analysis (hazard ratio [HR]=0.34, 95% confidence interval [CI]=0.16-0.67, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.0012) but not after adjusting for age, stage, treatment center, and residual tumor (HR=1.01, 95% CI=0.43-2.16, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.98). Grade 3 endometrioid carcinoma cases (N=30) were identical to grade 2 endometrioid carcinoma cases (N=23) with respect to survival in univariate analysis (HR=1.07, 95% CI=0.39-3.21, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.89) and immunohistochemical profile. Using histomorphology alone, interobserver agreement for the diagnosis of grade 3 endometrioid or high-grade serous carcinoma was 69%, which significantly increased (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001) to 96% agreement with the knowledge of WT1\/p53 status. Our data support the diagnostic value of WT1\/p53 status in differentiating between grade 3 endometrioid carcinoma and high-grade serous carcinoma. However, grade 3 and grade 2 endometrioid carcinomas showed no differences in immunophenotype or clinical parameters, suggesting that they could be combined into a single group.<\/jats:p>","DOI":"10.1097\/pas.0000000000001016","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T01:59:45Z","timestamp":1515376785000},"page":"534-544","source":"Crossref","is-referenced-by-count":45,"title":["High-grade Endometrioid Carcinoma of the Ovary"],"prefix":"10.1097","volume":"42","author":[{"given":"Hisham","family":"Assem","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Rambau","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada"},{"name":"Department of Pathology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sienko","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda E.","family":"Kelemen","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, College of Medicine"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/modpathol.2010.119","article-title":"High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression","volume":"23","author":"Roh","year":"2010","journal-title":"Mod Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/modpathol.2011.94","article-title":"Letter to the editor regarding \u2018Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression\u2019","volume":"24","author":"Gilks","year":"2011","journal-title":"Mod Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAS.0000000000000550","article-title":"Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors","volume":"40","author":"Lim","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molonc.2009.01.004","article-title":"Intercepting pelvic cancer in the distal fallopian tube: theories and realities","volume":"3","author":"Crum","year":"2009","journal-title":"Mol Oncol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000352","article-title":"Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series","volume":"39","author":"Morrison","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/path.4516","article-title":"Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden","volume":"236","author":"Anglesio","year":"2015","journal-title":"J Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","article-title":"An immunohistochemical algorithm for ovarian carcinoma typing","volume":"35","author":"K\u00f6bel","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/modpathol.2013.107","article-title":"Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles","volume":"27","author":"McConechy","year":"2013","journal-title":"Mod Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IGC.0000000000000492","article-title":"Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma","volume":"25","author":"Hoang","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/his.12934","article-title":"Significant frequency of MSH2\/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas","volume":"69","author":"Rambau","year":"2016","journal-title":"Histopathology"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"K\u00f6bel","year":"2016","journal-title":"J Pathol Clin Res"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0000000000000298","article-title":"The histomorphology of lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy","volume":"38","author":"Chui","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/modpathol.2011.211","article-title":"BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma","volume":"25","author":"McAlpine","year":"2012","journal-title":"Mod Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2015.11.008","article-title":"Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer","volume":"140","author":"Kelemen","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2016.156","article-title":"Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas","volume":"29","author":"Coatham","year":"2016","journal-title":"Mod Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/PGP.0000000000000291","article-title":"Immunohistochemical profiling of endometrial serous carcinoma","volume":"36","author":"Chen","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAS.0000000000000941","article-title":"Undifferentiated endometrial carcinomas show frequent loss of core switch\/sucrose nonfermentable complex proteins","volume":"42","author":"Kobel","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel","year":"2010","journal-title":"Int J Gynecol Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/PAS.0000000000000327","article-title":"Grading uterine endometrioid carcinoma: a proposal that binary is best","volume":"38","author":"Conlon","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0090-8258(90)90263-K","article-title":"Endometrioid carcinoma of the ovary: retrospective review of 145 cases","volume":"39","author":"Kline","year":"1990","journal-title":"Gynecol Oncol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/modpathol.2017.81","article-title":"Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups","volume":"30","author":"Parra-Herran","year":"2017","journal-title":"Mod Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/modpathol.2015.155","article-title":"Loss of switch\/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas","volume":"29","author":"Karnezis","year":"2016","journal-title":"Mod Pathol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e3181e1a3bb","article-title":"Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study","volume":"34","author":"K\u00f6bel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/PGP.0b013e31824c2372","article-title":"Architectural patterns of ovarian\/pelvic high-grade serous carcinoma","volume":"31","author":"Bromley","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PGP.0b013e31824d7445","article-title":"Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor","volume":"31","author":"Ali","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/PAS.0000000000000476","article-title":"Morphologic and molecular characteristics of mixed epithelial ovarian cancers","volume":"39","author":"Mackenzie","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/PGP.0000000000000251","article-title":"Calibration and optimization of p53, WT1, and Napsin A immunohistochemistry ancillary tests for histotyping of ovarian carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience","volume":"35","author":"Lee","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"R39-20230922","first-page":"4722","article-title":"Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas","volume":"62","author":"Schwartz","year":"2002","journal-title":"Cancer Res"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.2659","article-title":"Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma","volume":"220","author":"Madore","year":"2010","journal-title":"J Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201804000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:39:49Z","timestamp":1695422389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201804000-00014"}},"subtitle":["A Clinicopathologic Study of 30 Cases"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001016","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}